Cara Therapeutics (TVRD) Competitors $29.00 -0.86 (-2.88%) As of 05/30/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsSEC FilingsTrendsBuy This Stock TVRD vs. AUPH, MLYS, CVAC, PAHC, RCUS, COLL, WVE, SYRE, SNDX, and ARDXShould you be buying Cara Therapeutics stock or one of its competitors? The main competitors of Cara Therapeutics include Aurinia Pharmaceuticals (AUPH), Mineralys Therapeutics (MLYS), CureVac (CVAC), Phibro Animal Health (PAHC), Arcus Biosciences (RCUS), Collegium Pharmaceutical (COLL), Wave Life Sciences (WVE), Spyre Therapeutics (SYRE), Syndax Pharmaceuticals (SNDX), and Ardelyx (ARDX). These companies are all part of the "pharmaceutical products" industry. Cara Therapeutics vs. Aurinia Pharmaceuticals Mineralys Therapeutics CureVac Phibro Animal Health Arcus Biosciences Collegium Pharmaceutical Wave Life Sciences Spyre Therapeutics Syndax Pharmaceuticals Ardelyx Cara Therapeutics (NASDAQ:TVRD) and Aurinia Pharmaceuticals (NASDAQ:AUPH) are both small-cap manufacturing companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, dividends, community ranking, profitability, valuation, institutional ownership, risk, earnings and analyst recommendations. Does the MarketBeat Community favor TVRD or AUPH? Aurinia Pharmaceuticals received 576 more outperform votes than Cara Therapeutics when rated by MarketBeat users. Likewise, 73.41% of users gave Aurinia Pharmaceuticals an outperform vote while only 50.00% of users gave Cara Therapeutics an outperform vote. CompanyUnderperformOutperformCara TherapeuticsOutperform Votes150.00% Underperform Votes150.00% Aurinia PharmaceuticalsOutperform Votes57773.41% Underperform Votes20926.59% Does the media prefer TVRD or AUPH? In the previous week, Aurinia Pharmaceuticals had 2 more articles in the media than Cara Therapeutics. MarketBeat recorded 6 mentions for Aurinia Pharmaceuticals and 4 mentions for Cara Therapeutics. Aurinia Pharmaceuticals' average media sentiment score of 1.50 beat Cara Therapeutics' score of 0.58 indicating that Aurinia Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cara Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aurinia Pharmaceuticals 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk and volatility, TVRD or AUPH? Cara Therapeutics has a beta of 0.21, suggesting that its stock price is 79% less volatile than the S&P 500. Comparatively, Aurinia Pharmaceuticals has a beta of 1.16, suggesting that its stock price is 16% more volatile than the S&P 500. Do insiders and institutionals hold more shares of TVRD or AUPH? 44.7% of Cara Therapeutics shares are owned by institutional investors. Comparatively, 36.8% of Aurinia Pharmaceuticals shares are owned by institutional investors. 3.1% of Cara Therapeutics shares are owned by insiders. Comparatively, 12.2% of Aurinia Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Which has better earnings and valuation, TVRD or AUPH? Cara Therapeutics has higher earnings, but lower revenue than Aurinia Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCara TherapeuticsN/AN/AN/AN/AN/AAurinia Pharmaceuticals$247.30M4.29-$78.02M$0.2828.07 Do analysts recommend TVRD or AUPH? Cara Therapeutics presently has a consensus target price of $65.00, indicating a potential upside of 124.14%. Aurinia Pharmaceuticals has a consensus target price of $11.50, indicating a potential upside of 46.31%. Given Cara Therapeutics' higher possible upside, equities research analysts clearly believe Cara Therapeutics is more favorable than Aurinia Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cara Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Aurinia Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is TVRD or AUPH more profitable? Cara Therapeutics has a net margin of 0.00% compared to Aurinia Pharmaceuticals' net margin of -10.23%. Cara Therapeutics' return on equity of 0.00% beat Aurinia Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Cara TherapeuticsN/A N/A N/A Aurinia Pharmaceuticals -10.23%-4.41%-3.07% SummaryAurinia Pharmaceuticals beats Cara Therapeutics on 8 of the 13 factors compared between the two stocks. Get Cara Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TVRD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TVRD vs. The Competition Export to ExcelMetricCara Therapeutics IndustryManufacturing SectorNASDAQ ExchangeMarket Cap$271.47M$2.78B$2.01B$8.40BDividend YieldN/A13.01%2.64%4.17%P/E RatioN/A11.7522.6619.77Price / SalesN/A1,529,289.7156.90134.17Price / CashN/A15.8051.7234.64Price / BookN/A3.152.054.50Net IncomeN/A$81.02M-$330.96M$248.20M7 Day Performance-0.31%0.42%1.00%0.99%1 Month PerformanceN/A4.37%6.87%8.02%1 Year PerformanceN/A4.26%13.97%8.86% Cara Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TVRDCara TherapeuticsN/A$29.00-2.9%$65.00+124.1%N/A$271.47MN/A0.0080High Trading VolumeAUPHAurinia Pharmaceuticals3.4078 of 5 stars$7.86-1.6%$11.50+46.3%+46.1%$1.06B$247.30M-52.40300Positive NewsMLYSMineralys Therapeutics2.968 of 5 stars$15.73+0.4%$38.00+141.6%+26.7%$1.03BN/A-4.3228Positive NewsHigh Trading VolumeCVACCureVac3.9442 of 5 stars$4.53-2.2%$11.00+142.8%+20.2%$1.02B$523.70M8.24880News CoverageAnalyst ForecastPAHCPhibro Animal Health3.6848 of 5 stars$24.58-0.3%$20.00-18.6%+38.1%$996.33M$1.19B51.211,860Positive NewsRCUSArcus Biosciences2.5022 of 5 stars$8.98-5.6%$25.67+185.8%-39.9%$950.85M$141M-2.85500Positive NewsShort Interest ↑COLLCollegium Pharmaceutical4.0396 of 5 stars$29.39+0.7%$43.80+49.0%-9.4%$944.36M$664.28M12.67210Positive NewsWVEWave Life Sciences4.3576 of 5 stars$6.08-2.6%$21.17+248.1%-1.5%$937.14M$104.94M-5.48240Positive NewsSYRESpyre Therapeutics2.4763 of 5 stars$15.25-1.9%$53.40+250.2%-55.2%$919.21M$890,000.00-2.0473News CoveragePositive NewsSNDXSyndax Pharmaceuticals3.866 of 5 stars$10.57-0.5%$35.91+239.7%-45.2%$909.52M$43.72M-2.91110Positive NewsARDXArdelyx4.6613 of 5 stars$3.72-7.7%$10.39+179.3%-45.1%$890.03M$361.71M-23.2590Positive News Related Companies and Tools Related Companies Aurinia Pharmaceuticals Alternatives Mineralys Therapeutics Alternatives CureVac Alternatives Phibro Animal Health Alternatives Arcus Biosciences Alternatives Collegium Pharmaceutical Alternatives Wave Life Sciences Alternatives Spyre Therapeutics Alternatives Syndax Pharmaceuticals Alternatives Ardelyx Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TVRD) was last updated on 5/31/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredAs Bitcoin supply vanishes, this Trump-aligned token could explodeBitcoin's supply is being drained at unprecedented rates, but while most investors focus solely on Bitcoin, th...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cara Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cara Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy TVRD Stock Free TVRD Stock Alerts